Mogrify appoint Tom Graney Non-Executive Director, Audit Chair and Capital Markets Advisor

Mogrify Limited have announced the appointment of Tom Graney, CFA as Non-Executive Director, Audit Chair and Capital Markets Advisor. He joins senior biopharma industry executives Dr Jane Osbourn OBE (Chair) and Dr Lorenz Mayr, as an independent member of the Board of Directors.

Tom Graney said: “I am looking forward to working with the world-class team as they translate this deep expertise in cellular reprogramming into the advancement of internal programs in ophthalmology, immune-oncology and other disease areas through first-in-human studies.”

Mogrify is a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies.